Overview

To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD

Status:
Completed

Trial end date:
2009-06-17

Target enrollment:

Participant gender:

Summary

This is a 28 day study to evaluate the pharmacodynamic effect of pazopanib eye drops on the central retinal thickness of AMD patients

Phase:

Phase 2

Details

Lead Sponsor:

GlaxoSmithKline